Bristol-Myers Squibb 将来の成長

Future 基準チェック /26

Bristol-Myers Squibbの収益は年間5.9%で減少すると予測されていますが、年間利益は年間4.1%で増加すると予測されています。EPS は年間増加すると予測されています。自己資本利益率は 3 年後に51.9% 5.1%なると予測されています。

主要情報

4.1%

収益成長率

5.13%

EPS成長率

Pharmaceuticals 収益成長	12.0%
収益成長率	-5.9%
将来の株主資本利益率	51.93%
アナリストカバレッジ	Good
最終更新日	04 Nov 2025

今後の成長に関する最新情報

Recent updates

Bristol-Myers Squibb: Increased Global Breyanzi Sales Isn't Only Hematological Product Growth

Nov 03

We Think Bristol-Myers Squibb's (NYSE:BMY) Robust Earnings Are Conservative

May 05

Bristol-Myers Squibb: Extraordinary Dividend And FCF Yields Ready For Recession

Apr 22

Bristol-Myers Squibb's Rally Is Well Deserved, Albeit Warranting A Downgrade To Hold

Mar 25

Bristol-Myers Squibb: Why I'm Still Bullish

Mar 18

Bristol Myers Squibb (BMY): Undervalued Opportunity or Value Trap? A Deep Dive into 2024 Earnings and Fair Value

Feb 25Total Revenues: $12.3 billion, an 8% increase from the same period in 2023.

Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success

Feb 21

Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down

Feb 07

Bristol-Myers Squibb: Too Valuable Not To Hold This Pharma Gem, But Debt Challenges Remain

Jan 31

業績と収益の成長予測

NYSE:BMY - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2027	43,450	9,148	13,465	14,435	22
12/31/2026	44,004	9,249	13,640	13,364	25
12/31/2025	47,968	8,280	17,370	8,420	20
9/30/2025	48,034	6,039	15,302	16,621	N/A
6/30/2025	47,704	5,049	14,578	15,901	N/A
3/31/2025	47,636	5,419	13,086	14,310	N/A
12/31/2024	48,300	-8,948	13,942	15,190	N/A
9/30/2024	47,435	-7,258	13,803	15,003	N/A
6/30/2024	46,509	-6,541	12,945	14,163	N/A
3/31/2024	45,534	-6,148	12,509	13,724	N/A
12/31/2023	45,006	8,025	12,651	13,860	N/A
9/30/2023	44,935	8,285	11,468	12,914	N/A
6/30/2023	45,187	7,963	10,499	11,850	N/A
3/31/2023	45,848	7,311	10,860	12,224	N/A
12/31/2022	46,159	6,327	11,948	13,066	N/A
9/30/2022	46,738	6,677	12,946	13,817	N/A
6/30/2022	47,144	6,617	14,502	15,396	N/A
3/31/2022	46,960	6,251	15,347	16,195	N/A
12/31/2021	46,385	6,994	15,234	16,207	N/A
9/30/2021	45,468	-5,405	14,569	15,505	N/A
6/30/2021	44,384	-5,079	11,687	12,506	N/A
3/31/2021	42,810	-6,219	13,215	13,939	N/A
12/31/2020	42,518	-9,015	13,299	14,052	N/A
9/30/2020	39,395	-44	12,157	12,878	N/A
6/30/2020	34,862	-563	12,409	13,167	N/A
3/31/2020	31,006	954	9,939	10,757	N/A
12/31/2019	26,145	3,439	7,374	8,210	N/A
9/30/2019	24,173	5,655	7,583	8,458	N/A
6/30/2019	23,857	6,203	N/A	7,181	N/A
3/31/2019	23,288	5,144	N/A	6,155	N/A
12/31/2018	22,561	4,920	N/A	7,066	N/A
9/30/2018	22,037	1,432	N/A	4,628	N/A
6/30/2018	21,600	376	N/A	5,062	N/A
3/31/2018	21,040	919	N/A	5,589	N/A
12/31/2017	20,776	1,007	N/A	5,275	N/A
9/30/2017	20,570	4,229	N/A	5,601	N/A
6/30/2017	20,238	4,586	N/A	5,292	N/A
3/31/2017	19,965	4,836	N/A	4,147	N/A
12/31/2016	19,427	4,457	N/A	3,058	N/A
9/30/2016	18,471	3,366	N/A	2,226	N/A
6/30/2016	17,618	2,870	N/A	1,346	N/A
3/31/2016	16,910	1,574	N/A	978	N/A
12/31/2015	16,560	1,565	N/A	2,105	N/A
9/30/2015	16,531	1,775	N/A	1,793	N/A
6/30/2015	16,383	1,790	N/A	2,172	N/A
3/31/2015	16,109	2,253	N/A	3,157	N/A
12/31/2014	15,879	2,004	N/A	3,148	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BMYの予測収益成長率 (年間4.1% ) は貯蓄率 ( 3.3% ) を上回っています。

収益対市場: BMYの収益 ( 4.1% ) US市場 ( 16% ) よりも低い成長が予測されています。

高成長収益: BMYの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: BMYの収益は今後 3 年間で減少すると予想されています (年間-5.9% )。

高い収益成長: BMYの収益は今後 3 年間で減少すると予測されています (年間-5.9% )。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BMYの自己資本利益率は、3年後には非常に高くなると予測されています ( 51.9 %)。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/11/07 22:25
終値	2025/11/07 00:00
収益	2025/09/30
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Bristol-Myers Squibb Company 25 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。43

アナリスト	機関
David Toung	Argus Research Company
Charles Butler	Barclays
Luisa Hector	Berenberg

Bristol-Myers Squibb 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Bristol-Myers Squibb Company Updates Earnings Guidance for the Year 2025

Bristol-Myers Squibb Company Revises Earnings Guidance for the Year 2025

Price target increased by 7.4% to US$58.64

Recent updates

Executive VP exercised options and sold US$148k worth of stock

Bristol-Myers Squibb: Increased Global Breyanzi Sales Isn't Only Hematological Product Growth

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Bristol-Myers Squibb Company Updates Earnings Guidance for the Year 2025

New major risk - Revenue and earnings growth

Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (Deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus

Systimmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-Bren, an EGFR X HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors At ESMO 2025

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Orbital Therapeutics, Inc. for $1.5 billion.

Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease

Bristol Myers Squibb Builds on Eliquis (apixaban) Direct-To-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu (deucravacitinib)

Bristol-Myers Squibb Company Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma

Second quarter dividend of US$0.62 announced

Bristol-Myers Squibb Company to Report Q3, 2025 Results on Oct 30, 2025

Bristol-Myers Squibb Company Announces Quarterly Dividend, Payable on November 3, 2025

Executive VP & CFO notifies of intention to sell stock

Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (Mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025

Systimmune Inc. and Bristol Myers Squibb Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation to Systimmune Inc

Bristol Myers Squibb's Application for Breyanzi (Lisocabtagene Maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Bristol Myers Squibb Announces Management Changes

Bristol Myers Squibb's Supplemental New Drug Application for Sotyktu (Deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia

Bristol-Myers Squibb Company(NYSE:BMY) dropped from Russell 1000 Defensive Index

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of RemS Programs Within Bristol Myers Squibb's Cell Therapy Labels

First quarter dividend of US$0.62 announced

Bristol-Myers Squibb Company Announces Quarterly Dividend, Payable on August 1, 2025

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA -1 Trial Demonstrating Superiority of Sotyktu (Deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo®? (nivolumab) Across Multiple Solid Tumor Indications

Bristol Myers Squibb to Present Data at ASCO 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline

Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo®? (Nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with Pd-1 Expression 1%

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of 2seventy bio, Inc. (NasdaqGS:TSVT).

Bristol Myers Squibb Announces Executive Changes

We Think Bristol-Myers Squibb's (NYSE:BMY) Robust Earnings Are Conservative

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Bristol-Myers Squibb Company Revises Earnings Guidance for the Year 2025

Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia

Bristol-Myers Squibb: Extraordinary Dividend And FCF Yields Ready For Recession

Bristol Myers Squibb Announces U.S. Food and Drug Administration Updates CAMZYOS®? (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications

Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial

U.S. Food and Drug Administration Approves Bristol Myers Squibb's Opdivo (nivolumab) Plus Yervoy (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

U.S. Food and Drug Administration Approves Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) as Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo (nivolumab) Across Multiple Solid Tumor Indications

Us Rheumatologists Report Heightened Interest in Sotyktu for the Treatment of Psoriatic Arthritis Post Positive Trial Results, According to Spherix Global Insights

Upcoming dividend of US$0.62 per share

Bristol-Myers Squibb Company, Annual General Meeting, May 06, 2025

Bristol-Myers Squibb's Rally Is Well Deserved, Albeit Warranting A Downgrade To Hold

Bristol-Myers Squibb: Why I'm Still Bullish

CEO & Chairman exercised options and sold US$1.4m worth of stock

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of Car T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol-Myers Squibb Company to Report Q1, 2025 Results on Apr 24, 2025

Bristol-Myers Squibb Company (NYSE:BMY) agreed to acquire 2seventy bio, Inc. (NasdaqGS:TSVT) for approximately $280 million.

Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

Bristol Myers Squibb Receives European Commission Approval for Opdivo®? (Nivolumab) Plus Yervoy®? (Ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

Fourth quarter dividend of US$0.62 announced

Bristol-Myers Squibb Company Announces Quarterly Dividend on Common Stock, Payable on May 1, 2025

Bristol Myers Squibb (BMY): Undervalued Opportunity or Value Trap? A Deep Dive into 2024 Earnings and Fair Value

Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success

Bristol Myers Squibb Announces Opdivo Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company Provides Update on Phase 3 Relativity-098 Trial

Bristol Myers Squibb Announces Positive Topline Results for Breyanzi (Lisocabtagene Maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down

Bristol Myers Squibb Receives Positive Chmp Opinion for Car T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol-Myers Squibb: Too Valuable Not To Hold This Pharma Gem, But Debt Challenges Remain

Bristol Myers Squibb Presents Results from Checkmate -8Hw Analysis Evaluating Opdivo® (Nivolumab) Plus Yervoy® (Ipilimumab) Compared to Opdivo Monotherap

Bristol Myers Squibb Announces FDA Approval of Cobenfy

Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.62

Upcoming dividend of US$0.62 per share

Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Opdivo Qvantig™? (nivolumab and Hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo®? (Nivolumor Opdivo) Indications

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued